Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis
Ismail Sergin, Trent D Evans, Xiangyu Zhang, Somashubhra Bhattacharya, Carl J Stokes, Eric Song, Sahl Ali, Babak Dehestani, Karyn B Holloway, Paul S Micevych, Ali Javaheri, Jan R Crowley, Andrea Ballabio, Joel D Schilling, Slava Epelman, Conrad C Weihl, Abhinav Diwan, Daping Fan, Mohamed A Zayed, Babak Razani, Ismail Sergin, Trent D Evans, Xiangyu Zhang, Somashubhra Bhattacharya, Carl J Stokes, Eric Song, Sahl Ali, Babak Dehestani, Karyn B Holloway, Paul S Micevych, Ali Javaheri, Jan R Crowley, Andrea Ballabio, Joel D Schilling, Slava Epelman, Conrad C Weihl, Abhinav Diwan, Daping Fan, Mohamed A Zayed, Babak Razani
Abstract
Macrophages specialize in removing lipids and debris present in the atherosclerotic plaque. However, plaque progression renders macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysfunctional proteins and organelles. Here we show that a decline in the autophagy-lysosome system contributes to this as evidenced by a derangement in key autophagy markers in both mouse and human atherosclerotic plaques. By augmenting macrophage TFEB, the master transcriptional regulator of autophagy-lysosomal biogenesis, we can reverse the autophagy dysfunction of plaques, enhance aggrephagy of p62-enriched protein aggregates and blunt macrophage apoptosis and pro-inflammatory IL-1β levels, leading to reduced atherosclerosis. In order to harness this degradative response therapeutically, we also describe a natural sugar called trehalose as an inducer of macrophage autophagy-lysosomal biogenesis and show trehalose's ability to recapitulate the atheroprotective properties of macrophage TFEB overexpression. Our data support this practical method of enhancing the degradative capacity of macrophages as a therapy for atherosclerotic vascular disease.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
- Levine B. & Kroemer G. Autophagy in the pathogenesis of disease. Cell 132, 27–42 (2008).
- Evans T. D., Sergin I., Zhang X. & Razani B. Target acquired: selective autophagy in cardiometabolic disease. Sci. Signal. 10, eaag2298 (2017).
- Razani B. et al.. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 15, 534–544 (2012).
- Liao X. et al.. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 15, 545–553 (2012).
- Ouimet M. et al.. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 13, 655–667 (2011).
- Sergin I. et al.. Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis. Sci. Signal. 9, ra2 (2016).
- Consortium, C. A. D. C. D. G. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat. Genet. 43, 339–344 (2011).
- Wild P. S. et al.. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ. Cardiovasc. Genet. 4, 403–412 (2011).
- Yancey P. G. & Jerome W. G. Lysosomal sequestration of free and esterified cholesterol from oxidized low density lipoprotein in macrophages of different species. J. Lipid Res. 39, 1349–1361 (1998).
- Duewell P. et al.. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
- Sheedy F. J. et al.. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812–820 (2013).
- Emanuel R. et al.. Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae. Arterioscler. Thromb. Vasc. Biol. 34, 1942–1952 (2014).
- Settembre C. et al.. TFEB links autophagy to lysosomal biogenesis. Science 332, 1429–1433 (2011).
- Sardiello M. et al.. A gene network regulating lysosomal biogenesis and function. Science 325, 473–477 (2009).
- Sergin I., Evans T. D. & Razani B. Degradation and beyond: the macrophage lysosome as a nexus for nutrient sensing and processing in atherosclerosis. Curr. Opin. Lipidol. 26, 394–404 (2015).
- Settembre C. et al.. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat. Cell Biol. 15, 647–658 (2013).
- O'Rourke E. J. & Ruvkun G. MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability. Nat. Cell Biol. 15, 668–676 (2013).
- Elbein A. D., Pan Y. T., Pastuszak I. & Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology 13, 17R–27R (2003).
- Jain N. K. & Roy I. Effect of trehalose on protein structure. Protein Sci. 18, 24–36 (2009).
- Richards A. B. et al.. Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem. Toxicol. 40, 871–898 (2002).
- Schiraldi C., Di Lernia I. & De Rosa M. Trehalose production: exploiting novel approaches. Trends Biotechnol. 20, 420–425 (2002).
- Tanaka M. et al.. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148–154 (2004).
- Sarkar S., Davies J. E., Huang Z., Tunnacliffe A. & Rubinsztein D. C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282, 5641–5652 (2007).
- Rodriguez-Navarro J. A. et al.. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol. Dis. 39, 423–438 (2010).
- Kruger U., Wang Y., Kumar S. & Mandelkow E. M. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 33, 2291–2305 (2012).
- Castillo K. et al.. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 9, 1308–1320 (2013).
- Liu R., Barkhordarian H., Emadi S., Park C. B. & Sierks M. R. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 20, 74–81 (2005).
- Kim J. et al.. Amyloidogenic peptide oligomer accumulation in autophagy-deficient beta cells induces diabetes. J. Clin. Invest. 124, 3311–3324 (2014).
- Castillo K. et al.. Measurement of autophagy flux in the nervous system in vivo. Cell Death Dis. 4, e917 (2013).
- Klionsky D. J. et al.. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12, 1–222 (2016).
- Martina J. A. et al.. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal. 7, ra9 (2014).
- Ploper D. et al.. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc. Natl Acad. Sci. USA 112, E420–E429 (2015).
- Martinez J. et al.. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc. Natl Acad. Sci. USA 108, 17396–17401 (2011).
- Wolkers W. F. et al.. Temperature dependence of fluid phase endocytosis coincides with membrane properties of pig platelets. Biochim. Biophys. Acta 1612, 154–163 (2003).
- Settembre C. et al.. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095–1108 (2012).
- Roczniak-Ferguson A. et al.. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal. 5, ra42 (2012).
- Liu Y. & Levine B. Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 22, 367–376 (2015).
- Asano N. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13, 93R–104R (2003).
- Muller Y. L. et al.. Identification of genetic variation that determines human trehalase activity and its association with type 2 diabetes. Hum. Genet. 132, 697–707 (2013).
- Hara T. et al.. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885–889 (2006).
- Mizushima N. & Kuma A. Autophagosomes in GFP-LC3 transgenic mice. Methods Mol. Biol. 445, 119–124 (2008).
- Razani B. et al.. Fatty acid synthase modulates homeostatic responses to myocardial stress. J. Biol. Chem. 286, 30949–30961 (2011).
- Febbraio M. et al.. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105, 1049–1056 (2000).
- Rajamaki K. et al.. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
- Whiting M. J. & Watts J. M. Cholesterol crystal formation and growth in model bile solutions. J. Lipid Res. 24, 861–868 (1983).
- Steinbrecher U. P., Witztum J. L., Parthasarathy S. & Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 7, 135–143 (1987).
- Razani B. et al.. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121–38138 (2001).
- Semenkovich C. F., Coleman T. & Daugherty A. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J. Lipid Res. 39, 1141–1151 (1998).
- Folch J., Lees M. & Sloane Stanley G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497–509 (1957).
Source: PubMed